GAM
PTGX icon

Gotham Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Gotham Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.23M Sell
21,155
-440
-2% -$39K 0.01% 1076
2025
Q4 		$1.89M Sell
21,595
-603
-3% -$49.4K 0.01% 1059
2025
Q3 		$1.47M Sell
22,198
-15,089
-40% -$858K 0.01% 1086
2025
Q2 		$2.06M Buy
37,287
+14,215
+62% +$682K 0.01% 923
2025
Q1 		$1.12M Buy
+23,072
New +$967K 0.01% 972
2021
Q3 		– Sell
-4,793
Closed -$215K – 1102
2021
Q2 		$215K Buy
+4,793
New +$158K 0.01% 937

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Gotham Asset Management's PTGX Position: Q1 2026 in Review

Gotham Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 2% in Q1 2026, selling an estimated $39K and leaving 21,155 shares worth $2.23M. The position accounts for 0.01% of the portfolio, ranked #1076.

Gotham Asset Management first reported a position in PTGX in Q2 2021 and has held it in 6 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Gotham Asset Management held 21,155 shares of Protagonist Therapeutics worth $2.23M as of Q1 2026.
  • Gotham Asset Management sold 440 Protagonist Therapeutics shares in Q1 2026, an estimated $39K.
  • Protagonist Therapeutics made up 0.01% of Gotham Asset Management's portfolio in Q1 2026, its #1076 holding.
  • Gotham Asset Management first reported a position in Protagonist Therapeutics in Q2 2021 and has held it in 6 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.